Please assess the completion status of the following clinical trial:

Trial Title: Panobinostat and Sorafenib in Treating Patients With Liver Cancer That is Metastatic and/or Cannot Be Removed by Surgery

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically or cytologically confirmed hepatocellular carcinoma~  * Metastatic and/or unresectable disease~ * Child-Pugh score A or B~PATIENT CHARACTERISTICS:~* ECOG performance status 0-2~* Neutrophil count \> 1500/mm³~* Platelet count \> 100,000/mm³~* Hemoglobin ≥ 9 g/dL~* AST and ALT ≤ 2.5 times upper limit of normal (ULN) (≤ 5.0 times ULN if elevation due to disease involvement)~* Serum bilirubin ≤ 1.5 times ULN~* Serum creatinine ≤ 1.5 times ULN or creatinine clearance ≥ 50 mL/min~* Total serum calcium (corrected for serum albumin) or ionized calcium ≥ lower limit of normal (LLN)~* Serum potassium ≥ LLN~* Serum sodium ≥ LLN~* Serum albumin ≥ LLN or 3 g/dL~* LVEF ≥ LLN as demonstrated by baseline MUGA or ECHO~* TSH and free T4 within normal limits (thyroid hormone replacement therapy allowed)~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective double-method contraception (one being a barrier method) during and for 3 months after completion of study treatment~* INR \< 1.5 or PT/PTT within normal limits~* No impaired cardiac function including any 1 of the following:~  * QTc \> 450 msec on screening ECG~ * Congenital long QT syndrome~ * History of sustained ventricular tachycardia~ * History of ventricular fibrillation or torsades de pointes~ * Bradycardia, defined as heart rate \< 50 beats per minute~    * Patients with a pacemaker and heart rate ≥ 50 beats per minute are eligible~ * Myocardial infarction or unstable angina within the past 6 months~ * Congestive heart failure (NYHA class III-IV)~ * Right bundle branch block and left anterior hemiblock (bifascicular block)~* No uncontrolled hypertension~* No thrombolic or embolic events (e.g., cerebrovascular accident and transient ischemic attacks) within the past 6 months~* No pulmonary hemorrhage/bleeding event \> CTCAE Grade 2 within the past 4 weeks~* No other hemorrhage/bleeding event \> CTCAE Grade 3 within the past 4 weeks~* No unresolved diarrhea \> CTCAE grade 1~* No other concurrent severe and/or uncontrolled medical conditions~* No other primary malignancy within the past 5 years except curatively treated carcinoma in situ of the cervix or basal cell or squamous cell carcinoma of the skin~* No serious non-healing wound, ulcer, or bone fracture~* No evidence or history of bleeding diathesis or coagulopathy~* No significant traumatic injury within the past 4 weeks~* No known or suspected allergy to sorafenib tosylate or any other study drug~* No condition that would impair a patient's ability to swallow whole pills~* No malabsorption problem~* No known human immunodeficiency virus (HIV) or hepatitis C positivity (baseline testing for HIV and hepatitis C is not required)~* No significant history of non-compliance to medical regimens~PRIOR CONCURRENT THERAPY:~* No prior HDAC inhibitors, DAC inhibitors, HSP90 inhibitors, sorafenib tosylate, or valproic acid for the treatment of cancer~* More than 4 weeks since prior chemotherapy, investigational drugs, or major surgery and recovered~* More than 4 weeks since open biopsy~* More than 5 days since prior and no concurrent valproic acid for any medical condition~* No concurrent St. John's wort or rifampin~* No concurrent drugs with a risk of causing torsades de pointes~* No concurrent CYP3A4 inhibitors~* No concurrent radiotherapy~* No concurrent grapefruit, grapefruit juice, or Seville (sour) oranges~* No other concurrent investigational therapy~* No other concurrent anticancer agents~* Concurrent anticoagulation treatment with warfarin or heparin allowed

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LBH589 (Type: ACTIVE_COMPARATOR): This study utilizes a sequential dose-escalation design to define the MTD of LBH589 when combined with standard doses of sorafenib.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues